<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: Renhe Group and APR Applied Pharma Research Announce a License Agreement for the Distribution in the Chinese Market of an Innovative Solution to Treat Migraine	</title>
	<atom:link href="https://www.novumpr.nl/2017/01/19/renhe-group-and-apr-applied-pharma-research-announce-a-license-agreement-for-the-distribution-in-the-chinese-market-of-an-innovative-solution-to-treat-migraine/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.novumpr.nl/2017/01/19/renhe-group-and-apr-applied-pharma-research-announce-a-license-agreement-for-the-distribution-in-the-chinese-market-of-an-innovative-solution-to-treat-migraine/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=renhe-group-and-apr-applied-pharma-research-announce-a-license-agreement-for-the-distribution-in-the-chinese-market-of-an-innovative-solution-to-treat-migraine</link>
	<description>NovumPR press releases</description>
	<lastBuildDate>Thu, 19 Jan 2017 13:22:23 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.3</generator>
</channel>
</rss>
